Upcoming CatalystsDRUGSTAGECATALYST DATERemestemcel-L...

Upcoming Catalysts

	DRUG	STAGE	CATALYST DATE
1	Remestemcel-L (MSC-100-IV) acute graft versus host disease (aGVHD) in children	PDUFA priority review	09/30/2020 PDUFA date under priority review September 30, 2020. FDA Oncologic Drugs Advisory Committee meeting August 13, 2020 voted 8-2 supporting approval.
2	Rexlemestrocel (MPC-06-ID) Chronic low back pain	Phase 3	4Q 2020 Phase 3 data due 4Q 2020.
3	Rexlemestrocel Heart failure	Phase 3	4Q 2020 Phase 3 data due 4Q 2020.

Drug Pipeline

	DRUG	STAGE	NOTES
1	Remestemcel-L COVID-19	Phase 3	Phase 3 interim analysis recommended trial to continue - September 4, 2020. Enrollment to be completed 4Q 2020.
2	MPC-150-IM End-Stage Heart Failure with LVADs	Phase 2b	Phase 2b trial did not meet primary endpoint - November 11, 2018.
3	MPC-300-IV Rheumatoid arthritis	Phase 2	Phase 2 data released August 2016. Partnership required for Phase 3 development